An observational study in Obesity, Emotional Eating and Anhedonia, sponsored by TC Erciyes University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.
Sponsored by TC Erciyes University · Observational
Among 352 studies in Obesity with a site in Turkey — 72 open to participants now, 90 under way, 16 of them phase 3. Obesity · Turkey.
Among the 352 studies in Obesity with a site in Turkey, this one is the 103rd largest by planned enrollment of the 160 observational ones, is one of 59 that started in 2026, is one of 160 observational ones, reaches primary completion later than 47 of the 89 other live ones, and was the 327th registered.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
This study's planned enrollment of 60 is below the median of 114 across 2,154 observational studies indexed under Obesity.
Browse Obesity studies →72 of the 352 studies in Obesity with a site in Turkey are open now, in 12 countries. Each count lists the studies.
Of the 1,336 Obesity studies recruiting now, 377 (28%) set no upper age limit and 856 (64%) stop at 75 or younger; 168 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →352 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 59 started in 2026.
Median enrollment 64 across the 191 interventional studies, 82 across the 160 observational. Of the 236 that completed or were terminated, 7 (3%) have results posted.
34 of 352 have an industry lead sponsor. The 10 most frequent:
TC Erciyes University is the lead sponsor of 349 studies on the registry; 74 are open to participants now.
TC Erciyes University has 5 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
34 of the studies in Obesity with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
| NCT07769736Istinye UniversityMotivational Interviews Based on the Five-Step (5A) Model on Obesity Risk | 2026-11 |
| NCT07652151Fundación Pública Andaluza para la gestión de la Investigación en SevillaUNMASK: Unveiling the Pathobiology of Metabolic Dysfunction-Associated Steatotic Liver Disease for the Discovery of Novel Therapeutics and Biomarkers | 2026-11 |
| NCT07878299Sultan Abdulhamid Han Training and Research Hospital, Istanbul, TurkeyComparison of Segmental Body Composition Characteristics in Lipedema and Obesity | 2026-11-20 |
| NCT07846956Istanbul Saglik Bilimleri UniversityNAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World Study | 2026-11-30 |
Among the 352 studies in Obesity with a site in Turkey, from their registry updates:
This prospective observational study evaluates the longitudinal changes in anhedonia levels and emotional eating behaviors among adult individuals initiating glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight loss. Participants are assessed at baseline (treatment initiation) and after a 6-month follow-up period using standardized psychometric instruments.
Glucagon-like peptide-1 (GLP-1) receptor agonists are widely used in the management of obesity and type 2 diabetes by promoting satiety, delaying gastric emptying, and reducing appetite. Beyond peripheral metabolic regulation, GLP-1 receptors located in central reward circuitry suggest potential modulation of psychobiological processes, including reward processing, emotional eating, and anhedonia. However, longitudinal clinical data investigating the trajectory of anhedonia and emotional eating in patients using GLP-1 receptor agonists remain limited. This prospective, single-center observational cohort study is conducted at the Endocrinology and Metabolism Outpatient Clinic of Erciyes University. A total of 60 adult participants newly initiating GLP-1 receptor agonist therapy for weight management are enrolled.
Adult patients attending the Erciyes University Faculty of Medicine Endocrinology and Metabolism Outpatient Clinic who are newly prescribed GLP-1 receptor agonists for weight management.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult participants who have newly initiated GLP-1 receptor agonist treatment for weight reduction and are evaluated at baseline and at 6 months.
Change in Dimensional Anhedonia Rating Scale (DARS) Score
The DARS is a 17-item self-report questionnaire assessing state anhedonia across four domains (hobbies, food/drink, social activities, and sensory experiences). Each item is scored on a 5-point Likert scale from 0 ("Not at all") to 4 ("Extremely"), yielding a total score between 0 and 68. Lower scores indicate more severe anhedonia.
Time frame: Baseline and 6 months
Change in Emotional Eating Scale (EES) Score
The Turkish version of the Emotional Eating Scale (DYÖ) consists of 10 items assessing emotional eating across 3 subscales (inability to resist eating desire, food types, and feelings of guilt). Scored on a 4-point Likert scale from 0 ("Never") to 3 ("Always"), total scores range from 0 to 30. Higher scores reflect higher levels of emotional eating behavior.
Time frame: Baseline and 6 months
Plan to share: No
Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.
Of 791 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 6 months is below that.
Counting every sponsor, half of 836 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.